Shares Outstanding (Quarterly) Chart

View Shares Outstanding (Quarterly) for KRYS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shares Outstanding (Quarterly) Chart
Start Trial

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 29.60M
March 31, 2026 29.44M
December 31, 2025 29.19M
September 30, 2025 28.98M
June 30, 2025 28.93M
March 31, 2025 28.90M
December 31, 2024 28.79M
September 30, 2024 28.76M
June 30, 2024 28.71M
March 31, 2024 28.53M
December 31, 2023 28.24M
September 30, 2023 28.19M
June 30, 2023 27.97M
March 31, 2023 25.80M
December 31, 2022 25.76M
September 30, 2022 25.71M
June 30, 2022 25.66M
March 31, 2022 25.20M
December 31, 2021 25.21M
September 30, 2021 22.24M
June 30, 2021 22.20M
Date Value
March 31, 2021 22.20M
December 31, 2020 19.71M
September 30, 2020 19.71M
June 30, 2020 19.66M
March 31, 2020 17.37M
December 31, 2019 17.35M
September 30, 2019 17.31M
June 30, 2019 16.95M
March 31, 2019 14.44M
December 31, 2018 14.43M
September 30, 2018 10.98M
June 30, 2018 10.35M
March 31, 2018 10.31M
December 31, 2017 10.31M
September 30, 2017 10.24M
June 30, 2017 10.24M
March 31, 2017 10.24M
December 31, 2016 10.24M
September 30, 2016 10.24M
June 30, 2016 10.24M
March 31, 2016 10.24M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Marker Therapeutics, Inc. 16.67M
TG Therapeutics, Inc. 153.08M
Cytokinetics, Inc. 138.76M
ADMA Biologics, Inc. 225.36M
Alnylam Pharmaceuticals, Inc. 133.73M